Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1056_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
23 Мб
Скачать
458 G. Naldini et al.
Microfragmentation and simultaneous elimination of oily and bloody residual.
Aspiration of the activated nal product ready to be injected.
The great advantage brought by the Lipogems
®
system is to provide transplant­able clusters of lipoaspirate improving their engraftment. It is not a cell transplant but rather a tissue graft containing activated MSCs inside adipose clusters. Moreover, the importance of thickness of the tissue and its clusters to achieve an optimal engraftment is well known and dened through the experiences in skin grafting (Bianchi et al. 2013).
Comparing the nal product obtained after Lipogems
lipoaspirate, it was evident at the histological ndings that Lipogems
®
process with the common
®
samples maintained a better vascular stroma composed by slit-like capillaries and stromal stalks containing evident lumina of vascular channels; on the contrary, convent ional lipoaspirate had compressed and distorted microchannels. In addition, CD146 expression, which is coexpressed by endothelial cells and pericytes, was signi­cantly increased in the Lipogems
®
samples (Bianchi et al. 2013) and revealed also to have a long-lasting anti-inammatory activity probably sustained by a long-term survival of their MSCs (Nava et al. 2019).

3 Results

3.1 Literature Review
Only few studies investigated the outcomes of adipose-derived MSCs for the treatment of complex cryptoglandular stulas. The results with literature review are resumed in Table 1.
Garcia-Olmo et al. published a phase II clinical trial in 2009 (Garcia-Olmo et al.
2009) on 49 patients, but only 35 were affected by cryptoglandular stula. They
were treated with the closure of internal orice (IO) in association with injection of autologous adipose-derived stem cells, ASCs, along with brin glue (Group I) or only brin glue (Group II). At least 2 weeks prior to therapy administration, all patients underwent liposuction for manufacturing of ASCs to be used during the study or for cryopreservation in Group II. The reported healing rate for the two groups I-II at 1-year follow-up was 71% and 16%, respectively.
Guadalajara et al. reported in 2012 (Guadalajara et al. 2012) a low success rate of the group ASCs with brin glue which was 57.1% (lower than 71% previously reported). The group treated with brin glue only had 20% success rate (slightly higher than 16% previously published). These outcomes were at the end of the treatment including the rst and second procedure to close complex cryptoglandular stulas.
Herreros et al. published a Randomized Clinical Trial (RCT) in 2012 (Herreros et al. 2012) with 200 patients enrolled. They were subdivided into three groups: Group A treated with the only ASCs injection, Group B treated with ASCs injection in associat ion with brin glue, and Group C treated only with brin
28 Stem Cells in Cryptoglandular Anal Fistulas 459
(continued)
adverse events
considered related
to the treatment
(purulent
secretion, rectal
bleeding, and
pyrexia)
adverse events
Follow-up
(range) Complications
12 Not reported
71%
16%
ASC +
Fibrin
glue
Fibrin
glue
48 Total of 8.1% had
57.1%
20%
ASC +
Fibrin
These are at
glue
the end of
treatment
Fibrin
glue
including the
second
procedure
12 No serious
Group A
57.1%,
Group A
ASC
Group B
Group B
52.4%
Group C
ASC +
Fibrin
37.3%
glue
Group C
brin glue
/// 57.1% 46 Not reported
Table 1 Literature review
Age
Two steps
mean M:F Technique Subgroups Healing rate
35
Phase II
Author, year Study design N of patients
Garcia-
ASC+
IO closure
Total 49
14 CD
clinical trial
Olmo et al.
(2009)
8:13
7:6
41
40
1410Considering only
cryptoglandular
Phase II
clinical trial
Guadalajara
et al. (2012)
Two steps
ASC+
IO closure
A
47:17B36:24C44:15
B 47.2
C 50.8
RCT phase III 200 A 49.7
Herreros
et al. (2012)
Cellution
system +
IO closure
42.3 5:2 One step
7
Two had preop.
Colostomy
Observational
study
Borowski
et al. (2015)
460 G. Naldini et al.
abdominal wall
hematoma, One
Follow-up
(range) Complications
9(3–12) Three minor
Overall 73.7%
Group I
Group I 83.3%
Group II
First time
group
perianal abscess
57.1%
Group II
Recurrent
reactions or
20 (6–48) No adverse
Improvement
91.6%
group
SVF 60%
(31/52)
complications
Healing 50%
SVF 69.2%
Au- eASC
16%
Au- eASC
17%
(9/52)
Allo-
Allo-eASC
40%
eASC
23%
(12/52)
adverse events.
6 No serious
complete
/// 3 (20%)
One plug
extrusion, One
healing
8 (53.3%)
abdominal wall
partial healing
Age
mean M:F Technique Subgroups Healing rate
Author, year Study design N of patients
Table 1 (continued)
Lipogems
device +
19 48 7:12 One step
Pilot
observational
study
Naldini et al.
(2018)
IO closure
Cellution
system+
IO closure
24:21 One step
24
Cryptoglandular
Total
52 procedures for
Observational
study
Herreros
et al. (2019)
SVF
2 steps
45 patients
18 CD
Au- eASC+IO closure
Allo-
3RVF
eASC+
IO closure
In the
32/52
case,
brin glue
Was used
15 39.8 7:8 Two steps
Phase I
Dozois et al.
MSC-
MATRIX
clinical trial
(2019)
28 Stem Cells in Cryptoglandular Anal Fistulas 461
seroma, And three
perianal abscesses
Eleven AEs in
seven patients of
group A
16 events among
24
Group A 50%
Group A
Only
39 pts.
(10/20)
Group B
ASC +
Fibrin
9 patients in groupBNone of the AEs
completed
the follow-
26.3%
(5/19)
glue
Group B
up
Fibrin
glue
were related to the
treatment
Two steps
ASC+
A
16:7B14:7
A 50.1
B 50.8
Total of
56 patients out of
Phase III
clinical trial
Garcia-
Arranz et al.
IO closure
the 57 subjects
enrolled, 44 were
(2020)
randomized (ITT
population), and
39 underwent
follow-up (PP)
SVF Stromal Vascular Fraction, Au-eASC Autologous expanded adipose-derived stem cells, Allo-eASC Allogenic expanded adipose-derived stem cells, CD
MSC-loaded plug
Crohns Disease, RVF Rectovaginal stula, ASC autologous adipose-derived stem cells, ITT Intention-to-treat, PP per protocol population, MSC-MATRIX
462 G. Naldini et al.
glue and saline solution (placebo) injection. At 1-year follow-up, the healing rate was as follows: Group A 57.1%, Group B 52.4%, and Group C 37.3%. In each group, IO was always closed.
Recently in 2020, an RCT was published by Garcia-Arranz et al.(2020) which takes into account the results of previous phase II clinical trials (Garcia-Olmo et al.
2009; Guadalajara et al. 2012) and tried to correct the study design mistakes of the
FATT-1 trial (Herreros et al. 2012). It is a multicenter, randomized, single-blind clinical trial that enrolled 57 patients. Forty-four were included into the inte nt-to­treat group and divided into two subgroups: Group A was treated with ASCs associated with intralesional brin glue injection, and Group B received only intralesional brin glue. In both cases, partial stulectomy and closure of IO was always performed. The patients not healed after 16 weeks were eligible for retreatment. At 24 months follow-up, the healing rate was 50.0% in Group A and 26.3% in Group B. These results essentially conrmed what was previously reported.
Borowski et al. (2015) reported a personal experience on 7 patients with recurrent complex cryptoglandular stula-in-ano. All of them received one or more treatments prior to be enrolled in the study. Two of them had a colostomy to manage the perianal sepsis, and it was closed after stula healing. In this series, the technique used was different, and it was based on a single-step procedure using Celution 800/CRS system (Cytori Therapeutics Inc., San Diego, CA, USA) which generates the SVF that is the precursor of MSCs, derived from liposuction. The automated Celution process takes a total time of approximately 90–120 min, and it is based on enzymatic digestion. At 46 months of follow-up, the healing rate was 57.1%.
Naldini et al. (2018) published a pilot observational study including only 19 patients who were eligible according to the strict including criteria. The patients were divided into 2 groups: Group I in which it is the rst sphincter saving procedure, and Group II including those who had failed prior sphincter-saving procedures. The procedure was based on IO closure associated with autologous microfragmented adipose tissue injection obtained through Lipogems
®
system. The overall healing rate was 73.7–83.3% and 57.1%, respectively, for Group I and Group II. The procedure resulted to be safe, feasible, and reproducible enhancing complex anal stula healing.
Herreros et al. published in 2018 a compassionate use stem cell injection associated to the closure of IO through a ap for complex perianal stulas of patients who were not eligible for the previous reported RCT (Herreros et al.
2019).Itisanobservationalstudyinwhichonly24upto45patientshada
cryptoglandular stula. It is fairly heterogeneous because three different proce­dureswereusedtogetthenal product: autologous expanded adipose-derived stem cells (Au- eASC), allogenic expanded adipose-derived stem cells (Allo­eASC) which are a two-step procedure, and Celution system (SVF) which is a single step. At mean follow-up of 40 months, 91.6% had improvement and 50% complete healing. The success rate stratied according the procedure was SVF
69.2%, Au- eASC 16%, and Allo-eASC 40%.
28 Stem Cells in Cryptoglandular Anal Fistulas 463
At least, Dozois et al. (2019) reported a phase I clinical trial about the use of autologous mesenchymal stem cell-coated stula plug in patients with trans­phincteric cryptoglandular stulas. It is a two-step procedure based on lipo­aspiration and then a creation of the novel bioactive plug. At 6 months follow-up, three patients (20%) showed a complete healing while eight patients (53.3%) had only partial healing.
3.2 Personal Experience
From January 2015 to January 2019, 50 patients affected by cryptoglandular com­plex anal stula were treated with Micro-fragmented Autologous Adipose Tissue Injection (MAATI) associated with IO closure using ap. Total 41 belong to Group I (rst line treatment) and 9 to Group II (recurrent disease). The mean follow-up is 35 months (range 64–17) with an overall success rate of 76%, respectively 80.5% and 55.5% for Group I and II.
In the same interval period, 51 patients with the same characteristics were treated with conventional advancement ap: 39 belong to Group I (rst line treatment) and 12 to Group II (recurrent disease). The mean follow-up is 32 months (range 68–17) with an overall success rate of 58.8%. Group I and Group II had 61.5% and 50%, respectively.
The authors in the present series used very strict selection criteria excluding all the conditions that could add bias to the nal results interpretation trying to check the real effectiveness of MAATI. The exclusion criteria were the following: multiple stula tracts, acute abscess, inammatory bowel disease, HIV, HBV or HCV infec­tion, rectovaginal stula, personal therapy with anticoagulants, steroids or immunomodulants, anamnesis of pelvic radiotherapy, history of neoplasia within 5 years from the diagnosis, pregnancy, uncontrolled diabetes, coagulopathy, or connective tissue diseases. Only single track cryptoglandular complex anal stulas conrmed by pelvic magnetic resonance or three-dimensional 360 sound were enrolled.
Comparing the results reported would seem that MAATI contributes to the stula closure, showing its maximal effectiveness in those patients who were treated for the rst time with sphincter-saving procedu re just after seton placement (around 4– 6 weeks) to drain the acute phase.
transanal ultra-

4 Discussion and Conclusion

Anal stula is a rare proctologic condition according to European Medicines Agency (European Medicines Agency, Committee for Orphan Medicinal Products. AloselOrphan Maintenance Assessment Report. Accessed 10.2019,2018) whose treatment represents one of the most challenging procedures for proctologists because of the high rate of recurrence (Amato et al. 2020).
464 G. Naldini et al.
Moreover, the postoperative impaired anal continence rate may be not negligible, and it raises up to 53% after laying open an intersphincteric or transphincteric stula (Lunniss et al. 1994).
This background has led to a growing number of innovative procedures to treat complex anal stula trying to preserve the sphincters and their function. Among these, one of the latest techniques proposed is based on the well-known regenerative effect of the injection of MSCs.
Differently for other application elds, for complex anal stulas it was always associated to the combined treatment of internal orice. In fact, IO may be consid­ered as the turning point to maintain a chronic inammation thus preventing the spontaneous stula closure.
In all the studies conducted by Garcia-Olmo and collaborators, they frequently use the brin glue associated to the MSCs injection and IO closure. The reason in this case is to give to these cells a scaffold upon which they can proliferate. Their healing rate ranged between 50% and 60% reaching a peak of 69.2% in that group treated with the SVF obtained through the Celurion system (Herreros et al. 2012).
On the opposite, Naldini et al. used a novel device (Lipogems
®
) which allows a tissue graft. In this way, they get a double advantage. In fact, if on the one hand the one-step procedure reduces operative times, costs, and patientspsycho-physical involvement, on the other, it facilitates the surgeon to bypass the GMP restrictions guaranteeing a nal product which already contains MSCs with their scaffold. It does not need additives to facilitate the engraftment resulting to be a safe, feasible, and reproducible technique.
Interestingly, IO closure is not a conventional treatment strategy in Crohn-related anal stula where Laureti et al. (2020) recently reported 93.3% clin ical remission with absence of drainage upon gentle nger compression on the external orice while 66.7% presented combined (clinical and radiological) remission at 6 months postoperative follow-up. Almost half of the pati ents were administered with phar­macological agents during the study. Surely, CD opens a different pathogenic eld in which a relevant role is played by the disease activity; however, these are really promising results. They used the same one-step device (Lipogems
®
) used by Naldini et al. (2018) for cryptoglandular complex stulas in which the overall healing rate was 73.7%. In this series, anyhow, the IO was always closed with advancement ap.
A possible bias of all the studies conducted on complex cryptogland ular stulas is the difculty to clearly differentiate the contribution of the IO closure and the MSCs injection. However, considering the average advancement ap success rate of 66.7% (range 20–100%) (Kontovounisios et al. 2016), a contribution seems to be evident from the series of Naldini differently from the series of Garcia-Olmo and collabo­rators. These might be explained with the different surgical steps and devices used, focusing on the differences of MSCs plus brin glue injection instead of adipose tissue graft.
In the series of Dozois et al., instead, a further novel technique was reported in which they associate MSCs with plug placement. Although the follow-up is short, the results seem not so promising and this follows the published literature about plug surgery and its healing rates.
28 Stem Cells in Cryptoglandular Anal Fistulas 465
Unfortunately, there are no clear guidelines for MSCs use in surgical elds. In particular, for digestive tract whose diseases are generally well localized, the suggested application of MSCs is through a local injection (instead of systemic use as for systemic diseases) thus minimizing the side-effects keeping MSCs directly in contact with the injured tissue. Moreover, there is no consensus about the procedure and its surgical steps as how to inject the cells (needle size, speed, concentration, and volume amount) to achieve the maximal benecial effect (Georgiev-Hristov et al. 2018).
In addition, in the tissue graft therapy, the exact cell concentration contained inside the harvested and prepared nal product is not known, and it may probably vary from patient and adipose tissue features. This limit is also related to the undened amount of nal product needed to be injected to get an effective result. According to the authors’ experience, it should not be less than 12 cc because of almost 4–6 cc around the IO and 6–8 cc along the stula tract. Conversely, in the cell-based therapy prepared in the laboratory, cell concentration is well dened (usually 5 million cells/ml) and delivered in vials whose volume is known. Although the preoperative MSCs parameters should be dened to achieve a reproducible procedure, the two techniques have substantial differences (mainly the knowledge of MSCs amount injected) which would not seem directly related to the nal outcome.
However, a concept that needs to underline this tissue/cellular-based therapy is that they cannot be considered as ller agents. They should be injected neither inside the stula tract as for other biomaterials (Fabiani et al. 2017) because the cells will probably be lost very early with the postoperative secretions, nor too far from the stula walls thus preventing their contribution to the stula closure. MSCs need to be injected around the IO and along all the stula length to exploit their biologic activity promoting reparative mechanism for tissue regeneration and reducing the inamma­tion. Furthermore, the uniform distribution of the product injected may be inuenced by the presence of a brotic tissue which is fairly frequent in chronic stulas whereby a slow and careful injection is required in such cases.
An important limitation of the autologous tissue injection is the real availability of goodfat tissue to be easily harvested. Very thin patients, frequently those affected by CD but not only, are not suitable for these procedures, and in these cases the authors suggest to harvest fat tissue directly from the trochanteric regions if feasible. It is possible to harvest the tissue from these regions just after anterior abdom inal wall harvesting (in these cases, it is recommended to inltrate with not more of 120 cc modied Klein solution to avoid to get only uid instead of fat tissue). In case of preoperative plan to harvest only from both trochanteric regions (it is important to maintain symmetry as also for the abdominal wall), the patient needs to be placed on lateral position and turned from the left to the right side during the operation. This procedure requires longer operative time and a well-trained nurse team.
Another issue, not so frequently debated, is the liposuction surgical step. Since the rst case of lipo-aspiration was described by Illouz in 1983 (Illouz 1983), it became the most spread cosmetic procedure all over the world. The common perception of lipo-aspiration as a minor cosmetic procedure seems to underestimate the likelihood of major complications (Barillo et al. 1998;Zakineetal.2015). Indeed, the increase of
466 G. Naldini et al.
the number of procedures was linked to the complications occurrence and its rate increase. They range from minor complications such as seroma, edema, hematoma with minor bleeding, and local pain to more important, even life-threatening, compli­cations as pulmonary embolism, pneumothorax, and bowel perforation, occurring also in death in rare cases. There are some conditions considered as risk factors: thin abdominal wall, diastasis of the rectus abdominis muscles, abdominal distension that increases the abdominal convexity, umbilical or ventral hernia especially in those overweight patients in which they may be clinically misdiagnosed, and history of abdominal surgery with xed scar. To prevent complications, the authors learned the lesson from plastic surgeons (Taha and Tahseen 2020; Zakine et al. 2015)and accurately evaluated the abdomen with physical examination to detect hernias or wall weakness. In case of risk factors, a preoperative abdominal ultrasound is performed. In addition, the procedure is performed carefully harvesting fat tissue from the supercial and deep subcutaneous fat without abrupt gestures always checking the cannula orientation and its tip. At last, patients are evaluated 3–5h after the procedure maintaining the compressive bandage and then reexamined on the rst postoperative day before the discharge just after bandage removal. The only few cases of minor abdominal wall hematoma occurred in the authorsseries and were treated conservatively with topical eparine-like ointment administration. Hence, lipo­aspiration is an easy and fairly fast procedure to collect the amount of adipose tissue necessary to perform the surgical procedure for anal stula, but it needs to be carried out with care being aware of possible consequences so that they can be prevented and eventually early identied and treated.
In conclusion, MSCs certainly represent the future of regenerative medicine and surgery with their several application elds among which one is represented by complex anal stula treatment. Future researches need to better clarify their action mechanisms, and the differences between the two-step procedure with MSCs asso­ciated with an external scaffold and the one-step procedure with adipose tissue graft might explain the different outcomes.
Besides, it is necessary to identify a low-cost, easily reproducible, safe, and effective procedure whose results are proved on classicalcases of cryptoglandular complex anal stula. In fact, compassionate or last-chance attempts including complex or multiple recurrent stulas do not allow the colo-proctologist community to draw a nal conclusion on the real effect of MSCs to promote stula healing.

References

Alexander RW (2011) Autologous fat grafts as mesenchymal stromal stem cell source for use in
prolotherapy: a simple technique to acquire lipoaspirants. J Prolother 3(3):680–688 Amato A, Bottini C, De Nardi P, Giamundo P, Lauretta A, Realis Luc A, Piloni V (2020) Evaluation
and management of perianal abscess and anal stula: SICCR position statement. Tech
Coloproctol 24(2):127–143. https://doi.org/10.1007/s10151-019-02144-1
28 Stem Cells in Cryptoglandular Anal Fistulas 467
Atkin GK, Martins J, Tozer P, Ranchod P, Phillips RKS (2011) For many high anal stulas, lay open
is still a good option. Tech Coloproctol 15(2):143–150. https://doi.org/10.1007/s10151-011-
0676-6
Barillo DJ, Cancio LC, Kim SH, Shirani KZ, Goodwin CW (1998) Fatal and near-fatal complica-
tions of liposuction. South Med J 91(5):487–492. https://doi.org/10.1097/00007611-
199805000-00018
Bianchi F, Maioli M, Leonardi E, Olivi E, Pasquinelli G, Valente S, ... Ventura C (2013) A new
nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-
like elements by mild mechanical forces from human lipoaspirates. Cell Transplant 22(11):
2063–2077. https://doi.org/10.3727/096368912X657855 Bianco P (2009) The great MSC history review. Cell 2(4):313–319. https://doi.org/10.1016/j.stem.
2008.03.002.Mesenchymal
Borowski DW, Gill TS, Agarwal AK, Tabaqchali MA, Garg DK, Bhaskar PUD (2015) Adipose
tissue-derived regenerative cell-enhanced lipolling for treatment of cryptoglandular stulae-in-
ano: the ALFA technique. Surg Innov 22(6):593– 600. https://doi.org/10.1177/
1553350615572656
Caplan AI (1991) Mesenchymal stem cells. Chem Phys Lett 9:641–650. https://doi.org/10.1016/
0009-2614(70)87009-9
Caplan AI (2017) New MSC: MSCs as pericytes are sentinels and gatekeepers. J Orthop Res 35:
1151–1159. https://doi.org/10.1002/jor.23560 Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:
1076–1084. https://doi.org/10.1002/jcb.20886 Cheng F, Huang Z, Li Z (2019) Mesenchymal stem-cell therapy for perianal stulas in Crohns
disease: a systematic review and meta-analysis. Tech Coloproctol 23:613–623. https://doi.org/
10.1007/s10151-019-02024-8
Coleman SR (2006) Structural fat grafting: more than a permanent ller. Plast Reconstr Surg 118
(Suppl 3). https://doi.org/10.1097/01.prs.0000234610.81672.e7 Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, ... Péault B (2008) A perivascular
origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313.
https://doi.org/10.1016/j.stem.2008.07.003
da Silva Meirelles L, Caplan AI, Nardi NB (2008) In search of the in vivo identity of mesenchymal
stem cells. Stem Cells 26(9):2287–2299. https://doi.org/10.1634/stemcells.2007-1122 Dozois EJ, Lightner AL, Mathis KL, Chua HK, Kelley SR, Fletcher JG, ... Faubion WA (2019)
Early results of a phase I trial using an adipose-derived mesenchymal stem cell-coated stula
plug for the treatment of transsphincteric cryptoglandular stulas. Dis Colon Rectum 62(5):
615–622. https://doi.org/10.1097/DCR.0000000000001333 Estève D, Boulet N, Belles C, Zakaroff-Girard A, Decaunes P, Briot A, ... Galitzky J (2019)
Lobular architecture of human adipose tissue denes the niche and fate of progenitor cells. Nat
Commun 10(1):1– European Medicines Agency, Committee for Orphan Medicinal Products (2018) Alosel – Orphan
maintenance assessment report. Accessed 10 2019 Fabiani B, Menconi C, Martellucci J, Giani I, Toniolo G, Naldini G (2017) Permacolcollagen
paste injection for the treatment of complex anal stula: 1-year follow-up. Tech Coloproctol
21(3):211–215. https://doi.org/10.1007/s10151-017-1590-3 Friedenstein AJ, Chailakhjan RK, Lalykina KS (1870) The development of broblast colonies
in monolayer cultures of Guinea-pig bone marrow and spleen c ells. Cell Tissue Kinet 3:
393–403 Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV (1974) Stromal
cells responsible for transferring the microenvironment of the hemopoietic tissues. Transplan-
tation 17:331–340. https://doi.org/10.1097/00007890-197404000-00001 Friedenstein AJ, Chailakhyan RK, Gerasimov UV (1987) Transplantation in diffusion chambers.
Cell Tissue Kinet 20:263–272
16. https://doi.org/10.1038/s41467-019-09992-3